Literature DB >> 30977117

Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.

Guangdong Xie1,2, Haiyuan Yang1,2, Ding Ma1,2, Yihua Sun2,3, Haiquan Chen2,3, Xin Hu1,2, Yi-Zhou Jiang1,2, Zhi-Ming Shao1,2,4.   

Abstract

Lung metastasis is one of the leading causes of death for triple-negative breast cancer (TNBC). We sought to characterize the genetic alterations underlying TNBC lung metastases by integrating whole-genome sequencing and functional screening. Furthermore, we aimed to develop a metastasis-related gene signature for TNBC patients to improve risk stratification. In this prospective observational study, we first conducted whole-genome sequencing of paired primary tumor and lung metastasis from one TNBC patient to identify potential genetic driver alterations. An in vivo gain-of-function screening using an amplified open reading frame library was then employed to screen candidate genes promoting lung metastasis. Finally, we applied Cox proportional hazard regression modeling to develop a prognostic gene signature from 14 candidate genes in TNBC. Compared to the primary tumor, copy number amplifications of chromosomes 3q and 8q were identified in the lung metastasis. We discovered an enrichment of 14 genes from chromosomes 3q and 8q in mouse lung metastases model. We further developed and validated a four-gene signature (ENY2, KCNK9, TNFRSF11B and KCNMB2) that predicts recurrence-free survival and lung metastasis in TNBC. Our data also demonstrated that upregulated expression of ENY2 could promote invasion and lung metastasis of TNBC cells both in vitro and in vivo. In conclusion, our study reveals functional genes with copy number amplifications among chromosome 3q and 8q in lung metastasis of TNBC. And we develop a functional gene signature that can effectively stratify patients into low- and high-risk subgroups of recurrence, helping frame personalized treatments for TNBC.
© 2019 UICC.

Entities:  

Keywords:  gain-of-function screening; gene signature; recurrence-free survival; triple-negative breast cancer; whole-genome sequencing

Mesh:

Substances:

Year:  2019        PMID: 30977117     DOI: 10.1002/ijc.32329

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Identification of a prognosis‑associated signature associated with energy metabolism in triple‑negative breast cancer.

Authors:  Chao Li; Xujun Li; Guangming Li; Long Sun; Wei Zhang; Jing Jiang; Qidong Ge
Journal:  Oncol Rep       Date:  2020-06-23       Impact factor: 3.906

2.  Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.

Authors:  Shaoyan Lin; Hongnan Mo; Yiqun Li; Xiuwen Guan; Yimeng Chen; Zijing Wang; Binghe Xu
Journal:  BMC Cancer       Date:  2021-12-14       Impact factor: 4.430

3.  Diagnostic and Prognostic Nomograms for Lung Metastasis in Triple-Negative Breast Cancer.

Authors:  Jianguo Wang; Hongjun Zhao; Lifen Ye; Jingyong Li; Huaixiao Zhang; Chao Zhang; Qishuo Rao; Yurong Cai; Yiping Xu; Youyuan Deng
Journal:  Comput Math Methods Med       Date:  2022-08-11       Impact factor: 2.809

4.  Integrated multi-omics analysis identifies ENY2 as a predictor of recurrence and a regulator of telomere maintenance in hepatocellular carcinoma.

Authors:  Jian-Hua Li; Yi-Feng Tao; Cong-Huan Shen; Rui-Dong Li; Zheng Wang; Hao Xing; En-Si Ma; Hong-Yuan Xue; Quan-Bao Zhang; Zhen-Yu Ma; Zheng-Xin Wang
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

5.  Multi-Omics Profiling Suggesting Intratumoral Mast Cells as Predictive Index of Breast Cancer Lung Metastasis.

Authors:  Leyi Zhang; Jun Pan; Zhen Wang; Chenghui Yang; Wuzhen Chen; Jingxin Jiang; Zhiyuan Zheng; Fang Jia; Yi Zhang; Jiahuan Jiang; Ke Su; Guohong Ren; Jian Huang
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.